Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Semiconductors

Intel’s Turnaround Strategy Faces Major Setback as Qualcomm Declines Partnership

Felix Baarz by Felix Baarz
September 8, 2025
in Semiconductors, Tech & Software, Turnaround
0
Intel Stock
0
SHARES
172
VIEWS
Share on FacebookShare on Twitter

Intel’s ambitious foundry expansion plans have encountered a significant obstacle with Qualcomm’s CEO Cristiano Amon publicly stating his company will not utilize Intel’s manufacturing capabilities for its mobile processors. According to Amon, Intel’s production technology hasn’t yet reached the maturity required for power-efficient mobile chips. Instead, Qualcomm will maintain its existing manufacturing partnerships with TSMC and Samsung.

This rejection represents a substantial setback for Intel’s foundry division, which the chipmaker is counting on to drive its corporate turnaround. The company needs to attract major clients to justify the enormous investments being made in rebuilding its manufacturing infrastructure.

Financial Performance Highlights Challenges

Recent financial results underscore the magnitude of Intel’s challenges. The company’s second quarter 2025 results revealed operational losses exceeding $3 billion within its foundry business unit. While the division did achieve a modest 3% revenue increase, the enormous costs associated with regaining technological leadership continue to weigh heavily on profitability.

Intel’s overall corporate performance similarly disappointed investors. Q2 2025 brought stagnant revenue of $12.9 billion and a loss of $0.10 per share, falling significantly short of market expectations. In response to these disappointing results, management has initiated a comprehensive restructuring program.

Should investors sell immediately? Or is it worth buying Intel?

Key elements of Intel’s restructuring initiative include:
* Workforce reduction: Elimination of 15% of positions
* Restructuring costs: $1.9 billion recognized in the second quarter alone
* Q3 outlook: Earnings per share expected to break even at best
* Revenue forecast: Continued pressure anticipated

Government Intervention Provides Lifeline

As Intel’s financial situation grew increasingly precarious, the U.S. government intervened with substantial support. In late August, federal authorities converted CHIPS Act funding into an equity position representing nearly a 10% stake in the company. This direct capital injection aims to provide Intel with financial flexibility while eliminating uncertainties around government subsidies. Intel submitted the necessary documentation to the SEC regarding this arrangement in early September.

Artificial Intelligence Division Shows Promise

Amid struggles in both foundry operations and the traditional PC business, Intel’s artificial intelligence segment has emerged as a potential bright spot. The Data Center and AI division posted revenue of $3.9 billion, representing 4% growth. The company is positioning its Gaudi 3 AI accelerator to compete in the intensely competitive AI hardware market, though questions remain about whether this emerging business can offset the substantial losses in the foundry division.

The convergence of Qualcomm’s rejection, ongoing financial challenges, and substantial restructuring costs raises fundamental questions about whether Intel’s ambitious turnaround strategy can ultimately succeed.

Ad

Intel Stock: Buy or Sell?! New Intel Analysis from February 7 delivers the answer:

The latest Intel figures speak for themselves: Urgent action needed for Intel investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Intel: Buy or sell? Read more here...

Tags: Intel
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Xiaobai Maimai Stock
Asian Markets

Akso Health Group Pivots to Oncology with Global Patient Initiative

February 6, 2026
Jeld-WEN Stock
Analysis

Jeld-WEN’s Restructuring Plan Faces Scrutiny as Shares Languish

February 6, 2026
Next Post
Beyond Meat Stock

Beyond Meat Faces Critical Juncture as Financial Pressures Mount

Archer Aviation Stock

Archer Aviation: High-Flying Ambitions Meet Financial Turbulence

Abbott Laboratories Stock

Navigating Institutional Moves and Regional Headwinds: Abbott Laboratories' Stock Outlook

Recommended

Anticipating Navigator Holdings Quarterly Earnings Report Analysts Predict 030 EPS

2 years ago
Sandy Spring Stock

Sandy Spring Bancorp’s Final Chapter: A New Era Under Atlantic Union

3 months ago
Certara Stock

Certara Stock: Regulatory Milestone and Strong Fundamentals Fuel Recovery Hopes

6 months ago
Meta Stock

Meta Faces Mounting Pressure from Regulators and Strategic Shifts

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Navigating Change: Schnitzer Steel’s Digital and Structural Evolution

Akso Health Group Pivots to Oncology with Global Patient Initiative

Trending

Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

by Kennethcix
February 6, 2026
0

Deluxe Corporation is successfully shedding its legacy identity as a check-printing specialist. The company's strategic pivot toward...

Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026
Vir Biotechnology Stock

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

February 6, 2026
Tellurian Stock

Tellurian Acquisition Finalized as Woodside Takes Control

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Deluxe Stock Gains Momentum on Successful Fintech Transition
  • Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches
  • Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com